Open-house rebate agreement for multiple X-ray contrast agents
Titre original de l'avis
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen im Rahmen eines sog. Open-House-Modells zu diversen Röntgenkontrastmitteln (ATC-Code nach WHO: V08)
Score d'opportunité
Pourquoi ce score ?
Opportunité
46 / 100
Complexité
58 / 100
Facteurs de risque
Submissions are only accepted by the monthly cut-off; late receipt is pushed to the next month, which can delay market...
Only the explicitly named contractor categories may participate.
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Moderate opportunityFaits clés
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Mar 2027
- Non-exclusive supply/rebate agreement for pharmaceutical products, specifically X-ray contrast agents under ATC code V08.
- Open-house model with no individual negotiations and no delivery exclusivity.
Afficher le résumé complet
This is a German open-house supply arrangement for non-exclusive rebate agreements on multiple X-ray contrast agents (CPV 33600000) for AOK PLUS and associated health insurers. The notice states that participation is open to qualifying pharmaceutical companies, wholesalers, and public pharmacies, with no individual negotiations and no exclusivity. The procedure is unusual because the notice explicitly says it is not a public contract within the meaning of procurement law, although it is published in TED for transparency. Participation documents must be submitted electronically via DTVP after access approval, and the first submission deadline is 17 February 2025; afterwards, submissions are accepted by the 15th of each month until the agreement ends on 31 March 2027. No contract value is provided.
Risques
Submissions are only accepted by the monthly cut-off; late receipt is pushed to the next month, which can delay market...
Only the explicitly named contractor categories may participate.
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Technical
- Only pharmaceutical companies, wholesalers, or public pharmacies may act as contractors.
Eligibility
- Required submissions include the completed declaration of no exclusion grounds under §§ 123, 124 GWB.
Administrative
- Participation documents must be submitted fully and on time by the applicable monthly deadline.
Acheteur
Localisation
Erfurt, DEU
Site web
Profil acheteur
Identifiant
DE256878834
Activité
Health
Lots (1)
LOT-0001
Open-house rebate agreement for multiple X-ray contrast agents
Open-house, non-exclusive rebate agreement for a broad set of contrast media under ATC V08. The lot covers multiple named substances including Amidotrizoesäure, Ioxitalaminsäure, Iohexol, Iopamidol, Iopromid, Ioversol, Iodixanol, Iomeprol, Iobitridol, Bariumsulfat, and several gadolinium-based agents. The notice states that purchase volumes are unknown and minimum volumes are not guaranteed. Performance/place of use is stated as Dresden, Germany, but the agreement applies nationally within Germany.
Localisation
Durée
Catégorie
Date limite
Détails des critères
Siehe Kurzbeschreibung
Note sur la valeur
Afficher les données TED originales
Titre original du lot
Abschluss nicht-exklusiver Rabattvereinbarungen im Rahmen eines sog. Open-House-Modells zu diversen Röntgenkontrastmitteln (ATC-Code nach WHO: V08)
Description TED originale
Siehe Kurzbeschreibung
Détails de la procédure
- Date de publication
- 21 Jan 2025
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 43670-2025
Documents (1)
Appels d'offres similaires
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Belgium – Pharmaceutical products – Antimycotica
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Score d'opportunité
Pourquoi ce score ?
Opportunité
46 / 100
Complexité
58 / 100
Facteurs de risque
Submissions are only accepted by the monthly cut-off; late receipt is pushed to the next month, which can delay market...
Only the explicitly named contractor categories may participate.
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications